Company news

Quantum Cyber N.V. news in 2024

Quantum Cyber N.V.'s news releases, calls and decks from 2024, newest first.

View company

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

December 18, 2024

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

December 15, 2024

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

December 11, 2024

Mainz Biomed Announces Stock Split

November 28, 2024

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

November 11, 2024

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

October 20, 2024

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

October 7, 2024

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

September 17, 2024

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

September 3, 2024

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

July 24, 2024

Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test

July 18, 2024

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

July 8, 2024

Mainz Biomed Provides Half Year 2024 Corporate Update

July 1, 2024

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

June 2, 2024

Mainz Biomed Reports Results of 2024 Annual General Meeting

May 30, 2024

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

May 27, 2024

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

May 19, 2024

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

May 6, 2024

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

April 24, 2024

Mainz Biomed Reports Full Year 2023 Financial Results

April 8, 2024

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

March 4, 2024

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

February 21, 2024

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

February 20, 2024

Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

February 5, 2024

Mainz Biomed Provides Year-End Corporate Review 2023

January 8, 2024